Why Crispr Therapeutics AG Stock Bolted Higher in January – Motley Fool
Madison.com |
Why Crispr Therapeutics AG Stock Bolted Higher in January
Motley Fool A recent study, published ahead of its official peer-review, suggested that CRISPR-Cas9 based therapeutics might be too toxic for use in humans. If true, Crispr, and its fellow gene-editing brethren, may be sent back to the drawing board to look for a … Crispr Therapeutics AG (NASDAQ:CRSP) Forecasted to Earn FY2022 Earnings of ($3.83) Per Share Major Analyst Actions Under Review: CRISPR Therapeutics AG (CRSP), Callon Petroleum Company (CPE) Uncovering the next great stocks: Riot Blockchain, Inc. (RIOT), CRISPR Therapeutics AG (CRSP) |
